Mannkind

MannKind Corporation is an American biopharmaceutical company focused on the discovery, development, manufacture, and commercialization of therapies for diabetes, pulmonary arterial hypertension, and other diseases. The company is particularly associated with drug-delivery technologies designed to administer medicines through the lungs. Its best-known product is Afrezza, a rapid-acting inhaled insulin that uses MannKind's Technosphere formulation platform and a small, breath-powered inhaler. The company was founded in February 1991 by Alfred E. Mann, an entrepreneur and medical-device innovator whose name supplied the basis for the MannKind identity. The present corporate structure emerged from a 2003 combination of three Mann-controlled businesses: Pharmaceutical Discovery Corporation, CTL ImmunoTherapies, and Allecure. Through the 2001 acquisition of Pharmaceutical Discovery Corporation, MannKind obtained the Technosphere molecule and the MedTone inhaler technology. These assets became the foundation for the company's subsequent inhaled-insulin program. Afrezza represented an attempt to provide mealtime insulin without the need for a conventional subcutaneous injection. The product uses single-use cartridges containing pre-metered insulin doses and an inhaler that delivers the formulation into the lungs. Its pharmacological profile was designed for relatively rapid onset, with insulin concentrations reaching a peak approximately 12 to 15 minutes after inhalation and clearing more quickly than many injected formulations. The United States Food and Drug Administration approved Afrezza on June 27, 2014. After approval, MannKind entered an exclusive worldwide licensing and collaboration agreement with Sanofi on August 11, 2014. Under the arrangement, Sanofi assumed a major role in commercializing Afrezza, while the companies agreed to share the product's profits and losses. MannKind received a reported $150 million cash payment and was entitled to 35% of the relevant economics, with Sanofi receiving 65%. The partnership ended when MannKind announced termination of the agreement on January 5, 2016, following difficulties in establishing the product commercially. MannKind subsequently continued to commercialize and develop Afrezza while also pursuing other applications of its inhalation and formulation technologies. The company has described its broader pipeline as including therapies for pulmonary arterial hypertension and other pulmonary or systemic conditions. In March 2020, MannKind announced work with Immix Biopharma on a potential inhaled treatment for acute respiratory distress syndrome, illustrating the company's effort to extend its platform beyond diabetes. Leadership has changed several times since the company's founding. Alfred Mann served as chief executive until January 2015, when Hakan Edstrom became CEO and Mann became executive chairman. Edstrom left the CEO and president positions in November 2015, after which Mann served temporarily as interim CEO. Matthew Pfeffer was appointed CEO in 2016 and held the CEO and CFO roles concurrently. Michael Castagna became chief executive in May 2017. MannKind has maintained operations in both California and Connecticut, including a corporate presence in Westlake Village and the Afrezza manufacturing facility in Danbury. In 2022, Danbury became the company's official headquarters.

MannKind Corporation was founded in February 1991 by Alfred E. Mann, a medical-device entrepreneur and investor whose name became part of the company's identity. The business was not initially limited to a single commercial medicine. Its later structure brought together several Mann-associated ventures with interests in pharmaceutical discovery, cancer vaccines, and allergy-vaccine technology. A significant step came in 2001, when Pharmaceutical Discovery Corporation was acquired from Solomon Steiner. The transaction gave MannKind access to the Technosphere molecule and the MedTone inhaler. These technologies later became central to MannKind's development strategy because they provided a platform for formulating and administering medicines through inhalation. In 2003, Pharmaceutical Discovery Corporation, CTL ImmunoTherapies, and Allecure were combined into the corporate form that became MannKind Corporation. The company's lead development program was inhaled insulin. MannKind developed Afrezza as a rapid-acting mealtime insulin delivered through a compact inhaler using disposable cartridges with pre-measured doses. The product was intended to offer an alternative to injected prandial insulin. Clinical and pharmacokinetic work evaluated Technosphere formulations containing therapeutic proteins and examined how the inhaled route affected onset, duration, and safety. The FDA approved Afrezza in June 2014. Commercialization was initially pursued through a major partnership with Sanofi. In August 2014, MannKind granted Sanofi exclusive worldwide licensing rights for Afrezza. The companies agreed to share the product's profits and losses, with the stated allocation giving Sanofi 65% and MannKind 35%; MannKind also received a reported $150 million cash payment. The arrangement placed much of the early commercial responsibility with Sanofi, but the product did not achieve the expected level of market traction. MannKind and Sanofi ended the collaboration in January 2016, after which MannKind resumed a more direct role in the product's commercialization and development. The end of the Sanofi relationship was accompanied by continuing commercial and financial pressure. Reference material reports weak Afrezza sales and a decline in MannKind's trading volume by December 2017, although the supplied material does not provide a sufficiently documented share-price or financial series for inclusion here. The company continued to rely on Afrezza while seeking additional applications for its inhalation platform and exploring opportunities in pulmonary medicine. In 2015, leadership changed when Hakan Edstrom became chief executive and Alfred Mann moved into the executive-chairman role. Edstrom stepped down as CEO and president in November of that year, and Mann temporarily returned as interim CEO. Matthew Pfeffer was appointed CEO in 2016 and also served as chief financial officer. Michael Castagna became CEO in May 2017 and is identified in the available reference material as the current chief executive. MannKind has operated across California and Connecticut. It has maintained a corporate office in Westlake Village, California, while its Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury. Beyond diabetes, MannKind has described interests in pulmonary arterial hypertension and other diseases that may benefit from inhaled delivery. In March 2020, it announced a collaboration with Immix Biopharma to investigate an inhaled treatment for acute respiratory distress syndrome. This work reflected a continuing effort to apply the company's formulation and inhalation capabilities to additional therapeutic areas.

1. 2022Official headquarters moves to Danbury

   MannKind moved its official headquarters to Danbury, Connecticut.

   Source
2. 2020ARDS inhalation research collaboration

   MannKind announced work with Immix Biopharma on a possible inhaled treatment for acute respiratory distress syndrome.

   Source
3. 2017Michael Castagna becomes CEO

   Michael Castagna was named MannKind's chief executive in May.

   Source
4. 2016Sanofi collaboration ends

   MannKind announced termination of its Afrezza licensing and collaboration agreement with Sanofi.

   Source
5. 2014Afrezza receives FDA approval

   The FDA approved Afrezza, MannKind's inhaled rapid-acting insulin, on June 27.

   Source
6. 2014Sanofi licensing agreement

   MannKind granted Sanofi exclusive worldwide rights to commercialize Afrezza.

   Source
7. 2003Corporate combination creates the present MannKind structure

   Pharmaceutical Discovery Corporation, CTL ImmunoTherapies, and Allecure were combined into the company's present corporate form.

   Source
8. 2001Acquisition of Pharmaceutical Discovery Corporation

   MannKind acquired Pharmaceutical Discovery Corporation from Solomon Steiner, obtaining the Technosphere molecule and MedTone inhaler technology.

   Source
9. 1991MannKind is founded

   Alfred E. Mann founded MannKind Corporation in February 1991.

   Source

A specialty biopharmaceutical company centered on pulmonary delivery, inhaled medicines, and formulation technologies that can transport therapeutic compounds through the lungs.

• AfrezzaInhaled insulin2014

  Afrezza is a rapid-acting inhaled insulin product for mealtime use. It combines pre-metered, single-use cartridges with a small, breath-powered inhaler. MannKind's Technosphere formulation is designed to deliver insulin through the lungs, with pharmacokinetic studies describing a peak effect approximately 12 to 15 minutes after inhalation and removal from the body within roughly two to three hours. The FDA approved Afrezza in 2014. It was initially commercialized through Sanofi and later returned to MannKind's direct commercial and development activities.

• Technosphere platformDrug-delivery technology

  Technosphere is MannKind's inhalation-oriented formulation platform, acquired through the company's purchase of Pharmaceutical Discovery Corporation. It is designed to create formulations that can carry therapeutic molecules through the pulmonary route. MannKind has evaluated the platform with insulin and other therapeutic proteins and has sought applications in diseases beyond diabetes. The platform is used in combination with inhaler and cartridge systems rather than being a conventional standalone medicine.

• MedTone inhalerInhalation device

  The MedTone inhaler technology was obtained through the acquisition of Pharmaceutical Discovery Corporation and contributed to MannKind's inhaled-drug development capabilities. It represents the device component of the company's broader drug-delivery approach, in which an inhaler is paired with disposable cartridges containing a pre-measured pharmaceutical formulation.

• 2020Investigation of an inhaled ARDS treatmentProduct launch

  MannKind sought to apply its inhaled-drug platform to pulmonary diseases beyond diabetes.

  What changed. The company announced work with Immix Biopharma to try to develop an inhaled treatment for acute respiratory distress syndrome.

  Source
• 2016Termination of Sanofi collaborationStrategy

  Afrezza's early commercial performance was weaker than anticipated under the Sanofi partnership.

  What changed. MannKind announced that it was ending the exclusive licensing and collaboration agreement with Sanofi and resumed responsibility for Afrezza's commercial path.

  Aftermath. MannKind continued to develop and commercialize Afrezza while exploring broader applications for its inhalation technologies.

  Source
• 2014Grant of exclusive Afrezza commercialization rights to SanofiM&A

  After Afrezza received FDA approval, MannKind sought a large pharmaceutical partner to support worldwide commercialization of the inhaled insulin product.

  What changed. MannKind entered an exclusive global licensing and collaboration agreement with Sanofi. The arrangement allocated 65% of Afrezza profits and losses to Sanofi and 35% to MannKind and included a reported $150 million cash payment to MannKind.

  Aftermath. The collaboration did not deliver the expected commercial performance and was terminated in January 2016.

  Cash payment to MannKind. $150 million (2014 agreement)

  Source

• 2022MannKind moves official headquarters to Danbury

  The company moved its official headquarters to Danbury, Connecticut, where its Afrezza manufacturing facility is located.

  Other
  Source
• 2020MannKind announces inhaled ARDS treatment collaboration

  MannKind announced work with Immix Biopharma on a potential inhaled treatment for acute respiratory distress syndrome.

  Product launch
  Source
• 2016MannKind terminates Sanofi Afrezza collaboration

  MannKind announced the end of its licensing and collaboration agreement with Sanofi on January 5, 2016.

  Other
  Source
• 2014FDA approves Afrezza inhaled insulin

  The United States Food and Drug Administration approved Afrezza, MannKind's inhaled rapid-acting insulin product, on June 27, 2014.

  Product launchRegulation
  Source
• 2014MannKind enters global Afrezza licensing agreement with Sanofi

  MannKind granted Sanofi exclusive worldwide commercialization rights for Afrezza under a collaboration that included shared product economics and a reported $150 million cash payment to MannKind.

  M&A
  Source

1. MannKind Corporation
2. MannKind Corporation official website